期刊
CANCER LETTERS
卷 390, 期 -, 页码 58-66出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.12.034
关键词
LIMA1; EPLIN; p53; Invasion; Prognosis
类别
资金
- JSPS KAKENHI [16K07122, 16K09285, 16J05870]
- Grants-in-Aid for Scientific Research [26460944, 16J05870, 16K07122, 16K09285, 25430115] Funding Source: KAKEN
The tumor suppressor gene p53 is frequently mutated in human cancer. p53 executes various functions, such as apoptosis induction and cell cycle arrest, by modulating transcriptional regulation. In this study, LIM domain and Actin-binding protein 1 (LIMA1) was identified as a target of the p53 family using a cDNA microarray. We also evaluated genome-wide occupancy of the p53 protein by performing chromatin immunoprecipitation-sequencing (ChIP-seq) and identified two p53 response elements in the LIMA1 gene. LIMA1 protein levels were increased by treatment with nutlin-3a, a small molecule that activates endogenous p53. In addition, LIMA1 expression was significantly downregulated in cancers compared with normal tissues. Knockdown of LIMA1 significantly enhanced cancer cell invasion and partially inhibited p53-induced suppression of cell invasion. Furthermore, low expression of LIMA1 in cancer patients correlated with decreased survival and poor prognosis. Thus, p53-induced LIMA1 inhibits cell invasion, and the downregulation of LIMA1 caused by p53 mutation results in decreased survival in cancer patients. Collectively, this study reveals the molecular mechanism of LIMA1 down regulation in various cancers and suggests that LIMA1 may be a novel prognostic predictor and a therapeutic target for cancer. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据